KOREA WHO
-
-
CEO of ST Pharm
Sung Moo-je
Organic Chemistry Expert with 20 Years in Drug Development at Novartis, Expanding Active Pharmaceutical Ingredient Orders Expected
-
Last Updated on Jan 16, 2025
-
CEO of ST Pharm
Copy Url : https://www.koreawho.com/profile/SungMooje- Life Summary
Sung Moo-je is the President and CEO of ST Pharm.
He was born on December 30, 1965.
He graduated from Korea University's Department of Chemistry and earned a Master's degree in Organic Chemistry from Sogang University Graduate School.
He obtained a Ph.D. in Organic Chemistry from the University of Alabama in the United States and completed a postdoctoral fellowship at Harvard University.
He worked for over 20 years at Novartis, focusing on new drug development.
He then moved to ST Pharm, a subsidiary of the Dong-A Socio Group, where he served as the Head of the Innovation Strategy Development Division before being appointed as President and CEO in 2024.
He is committed to expanding active pharmaceutical ingredient contracts with global partner companies and strengthening drug development capabilities.
#SungMooje #STPharm #pharmaceuticalindustry #organicchemistry #drugdevelopment #KoreaUniversity #HarvardUniversity #Novartis #CEO #biotechnology
He was born on December 30, 1965.
He graduated from Korea University's Department of Chemistry and earned a Master's degree in Organic Chemistry from Sogang University Graduate School.
He obtained a Ph.D. in Organic Chemistry from the University of Alabama in the United States and completed a postdoctoral fellowship at Harvard University.
He worked for over 20 years at Novartis, focusing on new drug development.
He then moved to ST Pharm, a subsidiary of the Dong-A Socio Group, where he served as the Head of the Innovation Strategy Development Division before being appointed as President and CEO in 2024.
He is committed to expanding active pharmaceutical ingredient contracts with global partner companies and strengthening drug development capabilities.
#SungMooje #STPharm #pharmaceuticalindustry #organicchemistry #drugdevelopment #KoreaUniversity #HarvardUniversity #Novartis #CEO #biotechnology
- Life Summary
- Career Highlights & Challenges
- · ST Pharm's Corporate Structure
- · Delayed Supply in Q2 Leads to Weak Accumulated Performance in Q3
- · Selected as a 'Next-Generation World-Class Product Manufacturer' by the Ministry of Industry
- · Signed a KRW 26.9 Billion (US$19.23 Million) Supply Contract for Oligonucleotide Therapeutic Ingredients with a U.S. Biotech Company
- · Oral Colorectal Cancer Drug Candidate Vasoraparib Shows Positive Phase 1 Results
- · Dong-A Socio Group Chairman Kang Jung-seok Sells ST Pharm Shares
- · Conversion Price Adjustment for Convertible Bonds
- · Promoted to President and CEO of ST Pharm
- · Contract Signed with Ligachem Bio for ADC Linker Contract Development and Manufacturing
- · Construction of Second Oligonucleotide Facility; Production Capacity to Expand by Up to 2.5 Times by 2026
- · The Path Walked by ST Pharm
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos